Helix BioPharma Corp. Peer Review Publication of VDOS47

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the publication of a peered-reviewed V-DOS47 manuscript in “Frontiers in Immunology” journal. V-DOS47 is Helix’s second DOS47 development candidate following L-DOS47, which is currently in clinical testing for the treatment of non-small cell lung cancer.

The article, entitled “Development and Characterization of a Camelid Single Domain Antibody–Urease Conjugate That Targets Vascular Endothelial Growth Factor Receptor 2”, describes the design and construction of V-DOS47 for breast cancer and other potential indications. The paper can be accessed online at https://doi.org/10.3389/fimmu.2017.00956.

Helix-BioPharma-Corp.-Peer-Review-Publication-of-VDOS47-August-22-2017.pdf